Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
June 04, 2021 09:00 ET
|
Provectus Biopharmaceuticals Inc.
— Systemic disease control achieved in heavily pre-treated liver cancer patients — 83% DCR; median PFS of 9.2 months; median OS of 22.5 months; half of patients undergoing response...
Cellworks Singula™ Delivers Superior OS and DFS Predictions for Brain Cancer Patients in myCare-022-03 Clinical Trial
June 04, 2021 09:00 ET
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank
June 04, 2021 09:00 ET
|
Datavant
BOULDER, Colorado and SAN FRANCISCO, June 04, 2021 (GLOBE NEWSWIRE) -- Biodesix, a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, the leader in...
Cellworks Singula™ Accurately Predicts Clinical Outcome from Treatments in Patients with NSCLC
June 04, 2021 09:00 ET
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
Cellworks CBM Clinical Study Identifies Novel Biomarkers for ATRA Benefit and Failure in AML Patients
June 04, 2021 09:00 ET
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
Puma Exploration Reports Progress on Its 2021 Exploration Program at Williams Brook Gold Property in New Brunswick, Canada
June 04, 2021 09:00 ET
|
Puma Exploration Inc.
RIMOUSKI, Quebec, June 04, 2021 (GLOBE NEWSWIRE) -- Puma Exploration Inc., PUMA-TSXV, (the “Company” or “Puma”) is pleased to report progress on its current 2021 exploration program at the Williams...
Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
June 04, 2021 09:00 ET
|
Allogene Therapeutics, Inc.
ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and...
iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021
June 04, 2021 09:00 ET
|
iTeos Therapeutics Inc.
Updated results from a dataset of 43 patients showed durable responses and stable disease greater than six months with inupadenant monotherapy in five patients with advanced solid tumors,...
Gold X Announces Completion of Plan of Arrangement with Gran Colombia Gold Corp.
June 04, 2021 09:00 ET
|
Gold X Mining Corp.
VANCOUVER, British Columbia, June 04, 2021 (GLOBE NEWSWIRE) -- Gold X Mining Corp. (TSXV: GLDX) ("Gold X") is pleased to announce the completion of the previously announced plan of arrangement (the...
Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting
June 04, 2021 09:00 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., June 04, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, announced the presentation of positive clinical data from the first 12...
- April 24, 2024 15:46 ET EnergyX Taps Chevron Veteran, Allen Satterwhite, as President
- April 24, 2024 15:44 ET O2Gold Upsizes Private Placement and Provides Update on Quebec Aur Transaction